06/03/2026
This story deserves a place in the news.
Adding six months of life for someone facing advanced pancreatic cancer is meaningful. It matters. Those six months may mean more birthdays, more conversations, more memories, and more time with the people they love.
The researchers behind this work should be celebrated.
But we can't help but wonder if the larger story is still being overlooked.
For more than 40 years, researchers have been trying to silence a single genetic signal known as KRAS. Now, they may finally have a tool that can do it.
That's remarkable.
But what if the most important question isn't simply:
"How do we turn off KRAS?"
What if we also asked:
"What created an environment where KRAS became a problem in the first place?"
Nutrition.
Metabolic health.
Inflammation.
Environmental exposures.
Sleep.
Stress.
Social connection.
Purpose.
These variables rarely make headlines because they don't fit neatly into a single pill or a single target.
Yet they influence every cell in the body.
This is one of the reasons we have become so interested in longevity.
Over the years, we have noticed that most people don't have a health problem as much as they have a timing problem.
They're discovering important truths too late.
By the time pancreatic cancer is diagnosed, more than half of patients already have advanced disease.
Imagine if we invested the same passion, funding, and media attention into helping people create resilient, healthy internal environments decades before disease appears.
The future of healthcare is not choosing between breakthrough drugs and whole-person healing.
We need both.
The headlines will celebrate the pill.
But the bigger story may be learning how to create a body that is less hospitable to disease in the first place.
That's a conversation that deserves a much larger platform.
A clinical trial of 500 patients found daraxonrasib doubled average survival time in advanced pancreatic cancer, with fewer side effects than chemotherapy.